BACKGROUND Optimal upfront dual antiplatelet therapy (DAPT) duration after complex percutaneous coronary
A period of dual antiplatelet therapy (DAPT) is required after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) (1) (2) (3) . The pathophysiological rationale for DAPT after DES-PCI is predicated on the need to prevent stent-related thrombotic complications while vascular healing and platform endothelialization are ongoing, a process that seems to last between 1 and 6 months with newgeneration DES (1, 2, 4) . Whether to extend DAPT after this mandatory period to provide a broader atherothrombotic risk protection is currently a matter of debate (1) . Prolonged DAPT is associated with significant risk reductions in stent-and nonstent-related cardiac ischemic events, counterbalanced by an increased hazard of major bleeding, which is known to be associated with increased morbidity and mortality (1, 2, 4) . The subtle balance between the ongoing risk of ischemia and bleeding requires a careful evaluation of the individual patient's clinical and anatomic profile to identify those patients who might benefit from prolonged and/or higher-potency platelet inhibition and those who might be exposed to an excessive risk of bleeding (5) .
Coronary artery disease (CAD) complexity significantly influences the effectiveness of invasive revascularization strategies and is associated with a higher risk of adverse events, proportional to its severity and burden (5) . Patients undergoing PCI with more advanced CAD and challenging subsets of lesions require more complex procedures and remain at increased risk of mid-to long-term adverse ischemic events (5, 6) . Although initially the U.S. Food and Drug Administration gave on-label indication for DES use in simple, single, de novo coronary lesions in low-risk patients with CAD, many PCIs are currently performed in patients with high-risk clinical and anatomic features. Additionally, several reports linked specific procedural features with a higher risk of short-and long-term coronary thrombosis (7) (8) (9) (10) (11) . Within this background, patients with advanced CAD undergoing complex revascularization procedures may benefit from more aggressive long-term medical treatments and risk factor control. We therefore hypothesized that compared with a short-term (3 or 6 months) period of DAPT, a longer regimen of DAPT ($1 year) will reduce the risk of major adverse cardiac events (MACE) to a greater extent after complex percutaneous coronary revascularization. Table 2 ). Endpoint definitions in each included trial are reported in Online Table 3 .
METHODS
STATISTICAL ANALYSIS. Individual patient data was pooled in a single dataset and analyzed with a singlestage approach. The intention-to-treat population was used for the analyses, including all patients according to randomized treatment arm assignment (long-vs. short-term DAPT). Categorical variables are reported as counts and percentages and were compared by the Cochrane-Mantel-Haenszel test, using trial identifier as the stratification variable.
Continuous variables are reported as mean AE SD and were compared with 2-way analysis of variance, using trial identifier as the stratification variable. A simple Cox regression model was used to generate cumulative hazard function curves at median time of followup for descriptive purposes. Incidence rates and incidence rate differences for the main study endpoints (MACE, CTE, and major bleeding) are reported as 100 patient-days of follow-up. As in all of the included trials randomization was dissociated from actual treatment divergence (i.e., randomization after PCI and DAPT duration divergence at 6 months), implying that endpoint events occurring prior to treatment divergence could not be attributable to differences in DAPT duration, a landmark analysis at the time of treatment divergence in each trial was performed using a per-treatment cohort. (with values <25%, 25% to 50%, and >50% representing mild, moderate, and severe heterogeneity, Table 1 . Patients who underwent complex PCI more commonly had diabetes.
Clinical presentation was similar between groups.
Randomization assignment to shorter-or longer-term DAPT was well-balanced between the 2 groups.
Overall, new-generation DES were used in approximately 86% of patients across all trials. The prevalence of the complex PCI components in the overall population is illustrated in Figure 1 , and the overlap between complex PCI components in Online Table 4 .
At a median follow-up time of 392 days (interquartile range: 366 to 710 days), patients who underwent complex PCI had higher crude rates of MACE (Table 2, Figure 2A ) and CTE (Table 2, Figure 2B ), MI, definite or probable ST, target vessel revascularization, and mortality ( Table 2) . By multivariable Cox regression modeling (Table 3) , complex PCI remained strongly associated with increased risk of MACE, CTEs, definite or probable ST, and MI with a magnitude that was comparable to that of a history of prior MI or high-risk ACS presentation. Results were overall comparable following inclusion of left ventricular ejection fraction in the multivariable model (Online Table 5 ). Complex PCI was not associated with an increased risk of major bleeding at adjusted analyses 
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Prevalence of complex PCI components in the overall population. PCI ¼ percutaneous coronary intervention. 
LONG-VERSUS SHORT-TERM DAPT IN PATIENTS
WITH OR WITHOUT COMPLEX PCI. Baseline characteristics according to procedural complexity and randomized assignment to long-or short-term DAPT are illustrated in Online Table 6 . The differential median exposure time to DAPT between the long-and shortterm DAPT groups was 9 months. Results for longversus short-term DAPT in the complex and noncomplex PCI groups are reported in Table 4 . The effect of long-term DAPT was heterogeneous per PCI complexity, with a significant benefit in patients A B C Cumulative hazard curves for major adverse cardiac events (A), coronary thrombotic events (B), and major bleeding (C). Incidence rates are expressed as 100 patient-years of follow-up. CI ¼ confidence interval; HR ¼ hazard ratio; IRD ¼ incidence rate difference; PCI ¼ percutaneous coronary intervention.
Giustino et al. Table 7 ). There was no evidence of intertrial heterogeneity for all of the investigated endpoints (Online Table 8 ). Bias assessment is reported in Online Table 9 .
LONG-VERSUS SHORT-TERM DAPT IN PATIENTS WITH OR WITHOUT COMPLEX PCI ACROSS CLINICAL
AND ANGIOGRAPHIC SUBGROUPS. The effect of long-versus short-term DAPT in patients who underwent complex and noncomplex PCI across clinical subsets is reported in Table 5 . The effect of longversus short-term DAPT was uniform across subsets within both the complex and noncomplex PCI groups (Table 5 ) and across the high-risk angiographic subsets included in the complex PCI definition (Online Figure 4) .
DISCUSSION
The present study of more than 9,000 patients ran- Abbreviations as in Tables 1 and 2. JACC VOL. 68, NO. 17, 2016 Giustino et al. 
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Adjusted HRs (95% CI) Log Scale Values are number of events (%) unless otherwise indicated. *Defined as the composite of definite or probable ST or MI.
Abbreviations as in Tables 1 and 2. JACC VOL. 68, NO. 17, 2016 Giustino et al. The increased risk of major bleeding with prolonged DAPT is consistent with previous published reports and was uniform between PCI complexity groups (1). Given the greater anti-ischemic benefits of prolonged DAPT, alongside a similar bleeding hazard, the current findings support the hypothesis that patients who undergo complex coronary revascularization will benefit from upfront longer (>1 year)
DAPT duration. These findings may provide useful DAPT for $1 year significantly reduced the risk of major adverse cardiac events after complex PCI compared with 3 or 6 months of DAPT. Complex PCI was defined as the composite of 3 vessels treated, $3 stents implanted, $3 lesions treated, bifurcation with 2 stents implanted, total stent length >60 mm, or chronic total occlusion.
The y-axis displays the adjusted hazard ratios for long-term DAPT on risk of major adverse cardiac events. The x-axis displays the number of high-risk procedural features. Incidence rate differences per 100 patient-years of follow-up per number of high-risk procedural features are displayed above the plot. Complex PCI is associated with increased risk of major adverse cardiac events with a magnitude comparable to that of traditional clinical risk factors (i.e., prior myocardial infarction or acute coronary syndrome presentation). The magnitude of the anti-ischemic effect of long-term DAPT trended to be greater for increase in PCI complexity.
CI ¼ confidence interval; DAPT ¼ dual antiplatelet therapy; IRD ¼ incidence rate differences; PCI ¼ percutaneous coronary intervention. Cumulative hazard curves for long-term versus short-term DAPT for major adverse cardiac events (A), coronary thrombotic events (B), and major bleeding (C) in patients with or without complex PCI. Incidence rates are expressed as 100 patient-years of follow-up. Abbreviations as in Figures 2 and 4 . alaide@hsr.it. Abbreviations as in Tables 1 and 2 . 
